UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
32.10
+2.31 (7.75%)
Nov 19, 2026, 1:58 PM EST - Market open
UroGen Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 250.25 | 109.79 | 90.4 | 82.71 | 64.36 | 48.04 | |
Revenue Growth | 159.29% | 21.45% | 9.29% | 28.52% | 33.96% | 307.17% |
Cost of Revenue | 21.5 | 12.45 | 8.88 | 9.36 | 7.65 | 5.16 |
Gross Profit | 228.75 | 97.34 | 81.52 | 73.35 | 56.7 | 42.89 |
Selling, General & Admin | 186.48 | 155.1 | 120.05 | 93.27 | 82.84 | 87.54 |
Research & Development | 73.21 | 67.11 | 57.15 | 45.61 | 52.91 | 47.64 |
Operating Expenses | 259.69 | 222.2 | 177.2 | 138.89 | 135.74 | 135.18 |
Operating Income | -30.94 | -124.86 | -95.68 | -65.54 | -79.04 | -92.29 |
Interest Expense | -17.68 | -15.35 | -12.52 | -14.72 | -8.44 | - |
Interest & Investment Income | 3.47 | 5.97 | 8.9 | 2.64 | 0.94 | 0.37 |
Other Non Operating Income (Expenses) | -19 | -19.17 | -23.64 | -20.71 | -21.49 | -17.44 |
EBT Excluding Unusual Items | -64.15 | -153.42 | -122.94 | -98.32 | -108.03 | -109.37 |
Other Unusual Items | - | - | -1.1 | - | - | - |
Pretax Income | -64.15 | -153.42 | -124.04 | -98.32 | -108.03 | -109.37 |
Income Tax Expense | 1.6 | 0.08 | 2.83 | 3.92 | 1.76 | 1.45 |
Net Income | -65.75 | -153.49 | -126.87 | -102.24 | -109.78 | -110.82 |
Net Income to Common | -65.75 | -153.49 | -126.87 | -102.24 | -109.78 | -110.82 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 50 | 48 | 43 | 29 | 23 | 22 |
Shares Outstanding (Diluted) | 50 | 48 | 43 | 29 | 23 | 22 |
Shares Change | 5.29% | 12.22% | 48.70% | 26.43% | 2.05% | 2.60% |
EPS (Basic) | -1.31 | -3.19 | -2.96 | -3.55 | -4.81 | -4.96 |
EPS (Diluted) | -1.31 | -3.19 | -2.96 | -3.55 | -4.81 | -4.96 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -132.05 | -162.73 | -97.06 | -76.57 | -87.81 | -85.64 |
Free Cash Flow Per Share | -2.64 | -3.38 | -2.26 | -2.66 | -3.85 | -3.83 |
Gross Margin | 91.41% | 88.66% | 90.18% | 88.68% | 88.11% | 89.27% |
Operating Margin | -12.36% | -113.73% | -105.84% | -79.23% | -122.82% | -192.11% |
Profit Margin | -26.27% | -139.81% | -140.35% | -123.61% | -170.58% | -230.67% |
Free Cash Flow Margin | -52.77% | -148.22% | -107.37% | -92.57% | -136.45% | -178.27% |
EBITDA | -30.63 | -124.56 | -95.35 | -64.73 | -78.12 | -91.46 |
EBITDA Margin | -12.24% | -113.45% | -105.48% | -78.26% | -121.38% | -190.38% |
D&A For EBITDA | 0.31 | 0.31 | 0.33 | 0.8 | 0.92 | 0.83 |
EBIT | -30.94 | -124.86 | -95.68 | -65.54 | -79.04 | -92.29 |
EBIT Margin | -12.36% | -113.73% | -105.84% | -79.23% | -122.82% | -192.11% |